Data from: Pre- and post- treatment fold change plasma proteomics in metastatic NSCLC patients

Blood plasma samples were collected from advanced-stage NSCLC patients as
part of a clinical study (PROPHETIC; NCT04056247). All clinical sites
received IRB approval for the study protocol. Patient blood samples were
drawn at baseline (referred to as T0) and, on average, 4 weeks after the
treatment commenced, prior to the second dose of treatment (referred to as
T1). Blood samples were drawn into tubes containing EDTA as an
anticoagulant, and plasma was separated from the whole blood. The protocol
adheres to the Clinical and Laboratory Standards Institute (CLSI)
guidelines.